<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05113394</url>
  </required_header>
  <id_info>
    <nct_id>NCT05113394</nct_id>
  </id_info>
  <brief_title>Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy</brief_title>
  <acronym>PAPA</acronym>
  <official_title>Preventing Childhood Asthma Using Prophylactic House Dust Mite Allergen Immunotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Children's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Children's Hospital Medical Center, Cincinnati</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>George Washington University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Boston Children's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish efficacy and safety of HDM sublingual Immunotherapy (HDM-SLIT) by comparing&#xD;
      Odactra and placebo, when given sublingually for 3 years to high risk infants aged between 6&#xD;
      to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after&#xD;
      discontinuation of treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aim to prevent the development of asthma in children by intervening at a time when the&#xD;
      developing system in still amenable to immune modulation, by using the only therapy that has&#xD;
      proven ability to change the natural history of allergic diseases and induce clinical&#xD;
      remission. We hypothesize that three years of HDM Immunotherapy in high-risk infants will&#xD;
      prevent the development of asthma assessed over a period of 1.5 years after discontinuation&#xD;
      of treatment and HDM immunotherapy will result in (a) a significant reduction in the number&#xD;
      and pathogenic features of HDM-reactive TH2 cells, and (b) an increase in the numbers of&#xD;
      HDM-reactive TH and TREG cells expressing the interferon-response signature. The study is a&#xD;
      Randomized (1:1), double blinded, placebo controlled, parallel arms, multi-site, Phase II&#xD;
      study with a 3 year treatment phase and further 1.5 year follow-up phase. The study duration&#xD;
      for each participant is 4.5 years. Overall study duration is 84 months (7 years); which&#xD;
      include 9 months preparation and regulatory approvals, 15 months accrual, 36 months treatment&#xD;
      and 18 months follow-up observation period.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2024</start_date>
  <completion_date type="Anticipated">August 1, 2029</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2028</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized (1:1), double blinded, placebo controlled, parallel arms, multi-site, Phase II study; 3 year treatment phase with further 1.5 year follow-up phase.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>double blinded</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with Asthma</measure>
    <time_frame>1.5 years after discontinuation of 3 years of treatment</time_frame>
    <description>asthma diagnosis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">270</enrollment>
  <condition>Asthma</condition>
  <condition>Allergy</condition>
  <arm_group>
    <arm_group_label>Experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HDM sublingual Immunotherapy (HDM-SLIT) with Odactra® for 3 years to high-risk infants aged between 6 to 12 months at enrollment in preventing the development of asthma, assessed 1.5 years after discontinuation of treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered sublingually for 3 years to high-risk infants aged between 6 to 12 months with outcome of asthma development assessed 1.5 years after discontinuation of treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HDM sublingual Immunotherapy</intervention_name>
    <description>HDM-SLIT tablet (Odactra®/Acarizax®) is a rapidly dissolving, freeze-dried, oral lyophilizate for oromucosal treatment, which contains a 1:1 mixture of two allergen extracts derived for the cultivated house dust mites, D. pteronyssinus and D. farinae. These species are included in SLIT tablet and subcutaneous immunotherapy administered for the treatment of allergic rhinitis and asthma in the pediatric and adult populations. The tablet dissolves within seconds after contact with a wet surface such as the oral mucosa. Participants will be administered the drug sublingually for 3 years.</description>
    <arm_group_label>Experimental arm</arm_group_label>
    <other_name>dust mite sublingual immunotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo sublingual therapy</description>
    <arm_group_label>Placebo arm</arm_group_label>
    <other_name>placebo dust mite sublingual immunotherapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Aged 6 to 12 months of age&#xD;
&#xD;
          2. history of physician diagnosed atopic dermatitis OR&#xD;
&#xD;
          3. allergen sensitization OR&#xD;
&#xD;
          4. family history of asthma or allergy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of sensitization to house dust mite (SPT ≥3 mm OR sIgE (&gt; 0.35 kU/L)&#xD;
&#xD;
          2. Prematurity (&lt;37 weeks)&#xD;
&#xD;
          3. Failure to thrive&#xD;
&#xD;
          4. Need for oxygen for more than 5 days in the neonatal period&#xD;
&#xD;
          5. history of intubation or mechanical ventilation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>12 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wanda Phipatanakul, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston Children's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amparito Cunningham</last_name>
    <phone>857-218-5336</phone>
    <email>asthma@childrens.harvard.edu</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 19, 2021</study_first_submitted>
  <study_first_submitted_qc>October 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston Children's Hospital</investigator_affiliation>
    <investigator_full_name>Wanda Phipatanakul</investigator_full_name>
    <investigator_title>Professor of Pediatrics</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Factors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

